Replies to post #228173 on Amarin Corp Plc (AMRN)

[dukesking]

Sharinky. I'm in total agreement with you on this matter and have stated in previous post that I expect Vascepa will be more broadly used and supported by payers than most here think. I too think it should be covered as an essential medication with the broadest coverage available. For the same ' outside the box' reasons you've stated. I also think it should be broadly prescribed as an essential preventative drug to prevent the progression of CVD rather than to just treat CVD after it is well established. The lifetime costs to benefit ratio is very favorable to the payers. IMO